Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2021 - 08 - 05 save search
INDUS Announces Closing on the Acquisition of a 139,500 SF Industrial/Logistics Building in Lakeland, FL
Published: 2021-08-05 (Crawled : 22:00) - globenewswire.com
INDT 4 | $66.99 0.02% 0.0% 0
|
Real Estate and Rental and Leas...
|
| O: 0.01%
H: 0.07%
C: -1.42%
acquisition trial
Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
Published: 2021-08-05 (Crawled : 21:00) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 3.16%
H: 1.88%
C: 1.77%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.31%
H: 0.85%
C: 0.35%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.2%
H: 5.7%
C: 5.5%
treatment positive results trial topline
Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to MarketFinancing fully funds ONWARD™ Phase 3 trial until data read-out
Published: 2021-08-05 (Crawled : 17:00) - biospace.com/
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: -1.93%
H: 5.11%
C: 2.76%
phase 3 trial
Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome
Published: 2021-08-05 (Crawled : 16:00) - biospace.com/
SNPX | $4.6 0.66% 0.65% 14K
|
Professional, Scientific, and T...
|
| O: 0.92%
H: 4.82%
C: -7.04%
drug trial syndros bryostatin
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Live Ventures (LIVE) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Fraud
Published: 2021-08-05 (Crawled : 14:00) - prnewswire.com
LIVE 4 | $25.85 1.59% 20K
|
Retail Trade
|
| O: -1.49%
H: 8.38%
C: 0.45%
trial
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Zymergen (ZY) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations
Published: 2021-08-05 (Crawled : 14:00) - prnewswire.com
ZY | $2.43 0.0%
|
Mining, Quarrying, and Oil and ...
|
| O: 20.97%
H: 54.91%
C: 44.79%
trial merge
NAPCO Security Technologies To Attend The 10th Annual Needham Virtual Industrial Tech, Robotics, & Clean Tech 1x1 Conference
Published: 2021-08-05 (Crawled : 12:15) - prnewswire.com
NSSC | $43.96 1.48% 1.46% 260K
|
Producer Manufacturing
|
| O: -0.11%
H: 1.24%
C: 0.2%
security annual needham trial conference
Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)
Published: 2021-08-05 (Crawled : 12:15) - biospace.com/
XCUR 4 | $0.511 -5.42% -5.73% 19K
|
Commercial Services
|
| O: -1.42%
H: 1.44%
C: -5.04%
ongoing phase 1 results trial phase 1b phase 2b
Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial
Published: 2021-08-05 (Crawled : 12:15) - globenewswire.com
MNPR | $0.63 -3.08% -3.17% 39K
|
Health Technology
|
| O: 3.92%
H: 0.38%
C: -1.7%
phase 2 phase 2b trial
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
Published: 2021-08-05 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.05%
H: 0.23%
C: 0.09%
risk therapy phase 3 trial keytruda
Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson’s Disease and Multiple Sclerosis
Published: 2021-08-05 (Crawled : 12:00) - biospace.com/
CLNN 4 | $0.3374 0.69% 0.68% 300K
|
|
| O: 3.3%
H: 5.06%
C: 3.08%
multiple sclerosis disease phase 2 clinical trials positive results parkinson sclerosis trial topline
Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
lung cancer therapy cancer phase 3 trial
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
lung cancer therapy cancer phase 3 trial
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia
Published: 2021-08-05 (Crawled : 06:00) - prnewswire.com
LJPC | $6.22 0.0%
|
Health Technology
|
| O: 6.5%
H: 10.34%
C: 8.49%
acquired china phase 3 trial approval
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.